Journal Watch · Pharmacology & Therapeutics · 2026

Mitochondrial dysfunction in Alzheimer's disease: mechanisms, pathogenic interplay, and therapeutic opportunities.

Current evidence supports mitochondrial dysfunction as both a useful mechanistic basis for understanding AD progression and a biologically meaningful, though challenging, therapeutic target.

Dou B, Chen J, Zhao H et al.Pharmacology & Therapeutics3 min readPharma relevance 50/100

DOI: 10.1016/j.pharmthera.2026.109130PMID: 42869138Study type: review / perspective

TL;DR

Current evidence supports mitochondrial dysfunction as both a useful mechanistic basis for understanding AD progression and a biologically meaningful, though challenging, therapeutic target.

Key findings

  • This perspective also helps explain why disease progression is difficult to reverse once mitochondrial homeostasis has been broadly compromised.
  • At the same time, this framework also points to therapeutic opportunities, as the mechanisms driving the development and progression of mitochondrial dysfunction may be amenable to intervention.
  • However, many mitochondria-centered strategies remain preclinical or have yielded inconsistent clinical benefit.
  • Current evidence supports mitochondrial dysfunction as both a useful mechanistic basis for understanding AD progression and a biologically meaningful, though challenging, therapeutic target.

What they did

In AD, mitochondrial abnormalities impair energy production, compromise organelle quality control, disrupt calcium (Ca<sup>2+</sup>) homeostasis, and alter communication with the endoplasmic reticulum and glial cells. As these defects accumulate, neurons and glia become less able to maintain metabolic stability, redox balance, and synaptic function. Mitochondrial dysfunction is therefore relevant to AD not as a single isolated lesion, but as a convergent process through which metabolic failure, oxidative stress, mitochondrial DNA damage, inflammatory signaling, and defective cellular maintenance reinforce one another.

Full abstract (original)

Background: Alzheimer's disease (AD) remains a major cause of dementia, yet effective disease-modifying therapies are still limited. Although amyloid-β (Aβ) and tau pathology remain core features of AD pathogenesis, they do not fully explain how these pathological alterations drive progressive cellular dysfunction. Increasing evidence suggests that mitochondria are involved at this critical interface.

What they did: In AD, mitochondrial abnormalities impair energy production, compromise organelle quality control, disrupt calcium (Ca<sup>2+</sup>) homeostasis, and alter communication with the endoplasmic reticulum and glial cells. As these defects accumulate, neurons and glia become less able to maintain metabolic stability, redox balance, and synaptic function. Mitochondrial dysfunction is therefore relevant to AD not as a single isolated lesion, but as a convergent process through which metabolic failure, oxidative stress, mitochondrial DNA damage, inflammatory signaling, and defective cellular maintenance reinforce one another.

Results & conclusions: This perspective also helps explain why disease progression is difficult to reverse once mitochondrial homeostasis has been broadly compromised. At the same time, this framework also points to therapeutic opportunities, as the mechanisms driving the development and progression of mitochondrial dysfunction may be amenable to intervention. However, many mitochondria-centered strategies remain preclinical or have yielded inconsistent clinical benefit. Current evidence supports mitochondrial dysfunction as both a useful mechanistic basis for understanding AD progression and a biologically meaningful, though challenging, therapeutic target.

Abstract © the authors / Pharmacology & Therapeutics (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.pharmthera.2026.109130 · PubMed 42869138.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking Pharmacology & Therapeutics for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Pharmacology & Therapeutics study find?

Current evidence supports mitochondrial dysfunction as both a useful mechanistic basis for understanding AD progression and a biologically meaningful, though challenging, therapeutic target.

What type of study is this?

It is a review / perspective, published in Pharmacology & Therapeutics in 2026. In AD, mitochondrial abnormalities impair energy production, compromise organelle quality control, disrupt calcium (Ca<sup>2+</sup>) homeostasis, and alter communication with the endoplasmic reticulum and glial cells.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.pharmthera.2026.109130. PubMed ID: 42869138. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Dou B, Chen J, Zhao H et al.. Mitochondrial dysfunction in Alzheimer's disease: mechanisms, pathogenic interplay, and therapeutic opportunities.. Pharmacology & Therapeutics (2026). DOI: 10.1016/j.pharmthera.2026.109130.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/mitochondrial-dysfunction-in-alzheimer-s-disease-mechanisms-pathogenic-i-109130/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides